CRO Europital opens new UK site in response to urgent demand

The company will target working with small and medium biotechs who require a science-driven, rather than a volume-driven partner.
Europital – a global provider of medical management services for clinical research and drug development – is opening a UK site to further expand its services to the UK biotech industry. The company is already working with a number of UK partners and is forecasting compound growth nearly 30% of the next 3 years.
The Europital site will expand its operational team over the next few months and will target working with small and medium biotechs to design and execute projects, particularly for First in Man, Phase I and Phase II clinical studies.
The clinical research organization (CRO), which already partners with several biotechs in the UK, says it has seen a "clear gap in the market" for small innovators looking for a science focussed CRO that can provide detailed knowledge and therapeutic experience.
Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. The company says they can provide a medical department with real-world trial experience to implement study design and protocols.
Europital is planning to quickly expand its offering and will focus on providing expertise to partners in complex oncology indications, inflammatory diseases, immunology and infectious diseases studies.
The UK site opening will be used to leverage the company’s Phase III experience with clinical studies directly conducted at UK investigative sites.
Dr Mohamed El Malt, CEO and Chief Medical Officer of Europital said that much of the UK's cutting-edge innovation lies with smaller companies and spin outs and it is these organizations that really need the help of a science-driven CRO rather than that of a volume-driven large CRO that "usually won’t give the study the attention it needs".
"You often hear ‘follow the molecule’ in CRO circles. What we are doing is following the innovator and looking at where we can best help partners advanced targets more quickly through clinical trials," said Dr El Malt.
The company says that the shortage of senior experience in the market - primarily due to the number of trials currently underway - has resulted in almost 100% repreat business.
This development also opens up direct access to UK investigational sites for Europital's existing European and North American partners with Phase IIIstudies.
Related News
-
News Establishment of antiviral development centre for pandemic-level viruses
Researchers across several US institutions will come together to establish a centre for the research and development of antiviral drugs and therapeutics against pandemic-level viruses. -
News Pfizer boosts rare disease pipeline with $5.4B acquisition of Global Blood Therapeutics
The $5.4 billion deal marks Pfizer's fourth acquisition in the last nine months -
News Strategic partnership to rapidly bring monkeypox test kits to market
A strategic partnership between WeTrade Group and Jiqing Biomedical Technology hopes to rapidly bring monkeypox virus test kits to market and open antigen test sale channels. -
News Thermo Fisher Scientific announce expansion of cell culture media manufacturing site
The expansion of Thermo Fisher Scientific’s Grand Island, New York cell culture media manufacturing site offers increased redundant capacity in support of vaccine and biologic therapy development and manufacturing. -
News mRNA production partnership to scale-up COVID-19 vaccine development
GreenLight Biosciences and Samsung Biologics announce mRNA production partnership to scale mRNA vaccine production to a commercial level with Samsung's expanded mRNA drug substance manufacturing site. -
News Artificial intelligence used to uncover ‘dark matter of the plant kingdom’
Brightseed uses its AI-enabled platform to detect natural bioactives important to human health, also known as ‘nature’s dark matter’ -
News Taiwan’s TFBS partners with Univercells Technologies for use of bioreactor to develop GMP processes
TFBS will use Univercells’ scale-X™ carbo mid-scale fixed-bed bioreactor to support GMP viral vector operations -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance